Visceral Adiposity Index and Anti-VEGF Resistance in Diabetic Macular Edema

A retrospective cohort study of 298 patients with type 2 diabetes and center-involved diabetic macular edema (DME) initiating anti-VEGF therapy between January 2022 and December 2023. The research, authored by Mi Chen, analyzes the association between baseline Visceral Adiposity Index (VAI) scores and treatment resistance, finding 47.0% of patients were non-responders.

Use Cases

• Assess the prognostic ability of baseline Visceral Adiposity Index (VAI) scores for predicting anti-VEGF treatment resistance using ROC curve analysis.
• Perform multivariable logistic regression to identify independent factors, such as VAI, associated with a positive functional response defined by Best-Corrected Visual Acuity (BCVA) improvements.
• Conduct Kaplan-Meier analysis to evaluate time-to-response for patients stratified by the VAI optimal cut-off of 2.50.
• Analyze the distribution of baseline VAI scores between responder and non-responder patient cohorts to quantify metabolic dysfunction association.

Strengths

• Study includes 298 patient records, providing a substantive clinical cohort for analysis.
• Data covers a defined two-year time range from January 2022 to December 2023.
• Analysis employs multiple statistical methods: multivariable logistic regression, ROC curve analysis, and Kaplan-Meier survival analysis.

Limitations

• The dataset is very small in file size (16.2 KB), indicating it contains summary results or a manuscript, not the underlying raw patient-level data.
• As a retrospective study, findings demonstrate association but not causation, and may be subject to unmeasured confounding variables.
• The specific columns and sample data are unavailable, limiting direct analytical use without the full underlying dataset.

Provenance

Source

figshare

Collection Method

Retrospective cohort study analyzing patient medical records.

Time Range

January 2022 to December 2023

Freshness

null

Geography

null